Press Releases

Shanghai, China , December 4, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has been honored with the “Best Hong Kong Stock Connect Company” at the 10th Zhitong Caijing Listed Company Awards. This accolade not only reflects the high attention and affirmation from the capital markets regarding WuXi XDC’s exceptional performance and long-term investment value but also underscores the industry’s sustained confidence in its future growth prospects.

The selection process for these awards spanned over two months. An authoritative judging panel composed of investment institutions, analysts, industry associations, and media professionals conducted a comprehensive evaluation based on multiple criteria, including corporate growth performance over the past year, industry ranking, corporate governance, social influence, and capital market returns. The final winner list was determined after several rounds of rigorous selection. The “Best Hong Kong Stock Connect Company” award specifically aims to recognize the Hong Kong Stock Connect companies that demonstrate sound corporate governance, a prominent industry position, robust core operations, and have the ability to provide sustained and stable value returns to investors.

Mr. Michael Xi, CFO of WuXi XDC, stated, “WuXi XDC standing out among numerous participating enterprises signifies recognition from both the industry and investors, serving as a great encouragement for our company. Since its listing, WuXi XDC has been actively optimizing its global investor structure: the shareholding proportion through the Hong Kong Stock Connect has steadily increased, with trading activity significantly enhanced; the weighting of overseas long-term funds in its portfolio continues to grow, the coverage of public funds continues to expand, and the concept of value investing is increasingly prominent. Looking ahead, guided by our vision of ‘Linking Innovation to Health’ , we will provide global customers with higher-quality end-to-end CRDMO services and strengthen investor understanding of core value of WuXi XDC. Through regular investor communication, transparent information disclosure, and professional value interpretation, we aim to establish long-term mutual trust and cooperative relationships with global capital market, creating greater value for investors, partners, and the industry.”

As an industry-leading CRDMO in bioconjugates, WuXi XDC was successfully included in the “Hong Kong Stock Connect” just four months after its listing on the Main Board of the Hong Kong Stock Exchange in 2023, a testament to its outstanding performance. According to its 2025 interim financial report, WuXi XDC’s global customer base has been expanded to 563, and we have supported our customers in submitting nearly 100 IND applications cumulatively. Notably, 13 out of the top 20 global pharmaceutical companies (*ranked by 2024 revenue) have partnered with us in various stages of projects. By revenue, WuXi XDC currently holds over 22% market share globally, maintaining its leadership in the bioconjugate drug CRDMO sector.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com